Praxis Precision Medicines Provides Vormatrigine Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
Raymond James sees a 'unique buying opportunity' in this stock
June 2, 2026 4:00 PM EDTRaymond James believes the recent selloff in one biopharmaceutical companys shares has created an attractive entry point for investors, arguing that disappointment surrounding the company's vormatrigine program does not alter its core investment thesis.
In a research note, Raymond James analyst Tiago Fauth reiterated a Strong Buy rating on Praxis Precision Medicines (NASDAQ: PRAX) and maintained a Strong Buy rating despite a failed... More
